Literature DB >> 24576884

Human-induced pluripotent stem cell models of inherited cardiomyopathies.

Ioannis Karakikes1, Vittavat Termglinchan, Joseph C Wu.   

Abstract

PURPOSE OF REVIEW: This article provides an overview of the latest advances in in-vitro modeling of inherited cardiomyopathies using human-induced pluripotent stem cells (iPSCs). RECENT
FINDINGS: Inherited cardiomyopathies have been recently modeled by generating iPSCs from patients harboring mutations in genes associated with the pathogenesis of hypertrophic cardiomyopathy, dilated cardiomyopathy, and arrhythmogenic right ventricular cardiomyopathy/dysplasia.
SUMMARY: Patient-specific iPSCs and their differentiated cardiomyocytes (induced pluripotent stem cell-derived cardiomyocytes) now provide a novel model to study the underlying molecular mechanism of the pathogenesis of familial cardiomyopathies as well as for in-vitro drug screening and drug discovery.

Entities:  

Mesh：

Year:  2014        PMID： 24576884      PMCID： PMC4117923          DOI： 10.1097/HCO.0000000000000049

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN： 0268-4705            Impact factor:   2.161


  24 in total

1.  Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes.

Authors:  Ioannis Karakikes; Grant D Senyei; Jens Hansen; Chi-Wing Kong; Evren U Azeloglu; Francesca Stillitano; Deborah K Lieu; Jiaxian Wang; Lihuan Ren; Jean-Sebastien Hulot; Ravi Iyengar; Ronald A Li; Roger J Hajjar
Journal:  Stem Cells Transl Med       Date:  2013-12-09       Impact factor: 6.940

Review 2.  Clinical and genetic determinants of torsade de pointes risk.

Authors:  Andrew J Sauer; Christopher Newton-Cheh
Journal:  Circulation       Date:  2012-04-03       Impact factor: 29.690

3.  Production of de novo cardiomyocytes: human pluripotent stem cell differentiation and direct reprogramming.

Authors:  Paul W Burridge; Gordon Keller; Joseph D Gold; Joseph C Wu
Journal:  Cell Stem Cell       Date:  2012-01-06       Impact factor: 24.633

Review 4.  Mechanisms of disease: hypertrophic cardiomyopathy.

Authors:  Norbert Frey; Mark Luedde; Hugo A Katus
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

Review 5.  Inherited cardiomyopathies.

Authors:  Hugh Watkins; Houman Ashrafian; Charles Redwood
Journal:  N Engl J Med       Date:  2011-04-28       Impact factor: 91.245

Review 6.  Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Mark M Awad; Hugh Calkins; Daniel P Judge
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2008-04-01

7.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

Review 8.  Progress with genetic cardiomyopathies: screening, counseling, and testing in dilated, hypertrophic, and arrhythmogenic right ventricular dysplasia/cardiomyopathy.

Authors:  Ray E Hershberger; Jason Cowan; Ana Morales; Jill D Siegfried
Journal:  Circ Heart Fail       Date:  2009-05       Impact factor: 8.790

9.  A mouse model of familial hypertrophic cardiomyopathy.

Authors:  A A Geisterfer-Lowrance; M Christe; D A Conner; J S Ingwall; F J Schoen; C E Seidman; J G Seidman
Journal:  Science       Date:  1996-05-03       Impact factor: 47.728

10.  Human cardiomyopathy mutations induce myocyte hyperplasia and activate hypertrophic pathways during cardiogenesis in zebrafish.

Authors:  Jason R Becker; Rahul C Deo; Andreas A Werdich; Daniela Panàkovà; Shannon Coy; Calum A MacRae
Journal:  Dis Model Mech       Date:  2011-01-18       Impact factor: 5.758
View more
  12 in total

1.  Manipulation-free cultures of human iPSC-derived cardiomyocytes offer a novel screening method for cardiotoxicity.

Authors:  Sheeja Rajasingh; Dona Greta Isai; Saheli Samanta; Zhi-Gang Zhou; Buddhadeb Dawn; William H Kinsey; Andras Czirok; Johnson Rajasingh
Journal:  Acta Pharmacol Sin       Date:  2018-04-05       Impact factor: 6.150

Review 2.  Induced pluripotent stem cells for cardiovascular disease: from product-focused disease modeling to process-focused disease discovery.

Authors:  Katherine A Campbell; Andre Terzic; Timothy J Nelson
Journal:  Regen Med       Date:  2015-10-06       Impact factor: 3.806

Review 3.  Hold or fold--proteins in advanced heart failure and myocardial recovery.

Authors:  Claudius Mahr; Rebekah L Gundry
Journal:  Proteomics Clin Appl       Date:  2015-01-02       Impact factor: 3.494

4.  Identifying the Transcriptome Signatures of Calcium Channel Blockers in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.

Authors:  Chi Keung Lam; Lei Tian; Nadjet Belbachir; Alexa Wnorowski; Rajani Shrestha; Ning Ma; Tomoya Kitani; June-Wha Rhee; Joseph C Wu
Journal:  Circ Res       Date:  2019-05-13       Impact factor: 17.367

Review 5.  Clinical and Mechanistic Insights Into the Genetics of Cardiomyopathy.

Authors:  Michael A Burke; Stuart A Cook; Jonathan G Seidman; Christine E Seidman
Journal:  J Am Coll Cardiol       Date:  2016-12-27       Impact factor: 24.094

Review 6.  Engineering hiPSC cardiomyocyte in vitro model systems for functional and structural assessment.

Authors:  Alison Schroer; Gaspard Pardon; Erica Castillo; Cheavar Blair; Beth Pruitt
Journal:  Prog Biophys Mol Biol       Date:  2018-12-20       Impact factor: 4.799

7.  Prospects for In Vitro Myofilament Maturation in Stem Cell-Derived Cardiac Myocytes.

Authors:  Jonas Schwan; Stuart G Campbell
Journal:  Biomark Insights       Date:  2015-06-10

8.  Optical-flow based non-invasive analysis of cardiomyocyte contractility.

Authors:  Andras Czirok; Dona Greta Isai; Edina Kosa; Sheeja Rajasingh; William Kinsey; Zoltan Neufeld; Johnson Rajasingh
Journal:  Sci Rep       Date:  2017-09-04       Impact factor: 4.379

9.  Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation.

Authors:  Yueh Chien; Chian-Shiu Chien; Huai-Chih Chiang; Wei-Lin Huang; Shih-Jie Chou; Wei-Chao Chang; Yuh-Lih Chang; Hsin-Bang Leu; Kuan-Hsuan Chen; Kang-Ling Wang; Ying-Hsiu Lai; Yung-Yang Liu; Kai-Hsi Lu; Hsin-Yang Li; Yen-Jen Sung; Yuh-Jyh Jong; Yann-Jang Chen; Chung-Hsuan Chen; Wen-Chung Yu
Journal:  Oncotarget       Date:  2016-12-27

10.  Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.

Authors:  Francesco Lodola; Diego Morone; Marco Denegri; Rossana Bongianino; Hiroko Nakahama; Lucia Rutigliano; Rosanna Gosetti; Giulia Rizzo; Alessandra Vollero; Michelangelo Buonocore; Carlo Napolitano; Gianluigi Condorelli; Silvia G Priori; Elisa Di Pasquale
Journal:  Cell Death Dis       Date:  2016-10-06       Impact factor: 8.469
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.